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The studies outlined in this thesis provide several new insights into Msln-related pathways
necessary for peritoneal immune responses and mucosal repair. We found that Msln and its
binding partner mucin 16 from mesothelium influenced peritoneal and pleural macrophage
differentiation. We found that Msln was required for proper tissue repair after colonic biopsy
injury and was required for maximal polyp growth in APCMin/+ mice. Overall, this work describes
mesothelial and epithelial-derived factors that are important for tissue resident macrophage
differentiation and wound repair after colonic mucosal injury. Understanding the complex
interactions between stromal cells and immune cells will lead to better treatments for intestinal
diseases such as inflammatory bowel disease and tumor associated macrophage-mediated
tumorigenesis.
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CHAPTER ONE: INTRODUCTION

Development of Tissue Resident Macrophage
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Chapter 1: Introduction
Tissue resident macrophages
Macrophages were first described by Élie Metchnikoff in 18831. They are widely distributed
throughout the body and are present in the lymphoid organs, liver, lungs, gastrointestinal tract,
central nervous system, bone, and skin. Macrophages are critical components of the innate and
adaptive immune responses, and they are the first line of defense against foreign invaders through
phagocytosis of pathogens2,3. The recent outburst of interest in genetic, evolutionary, and
biochemical aspects of host-pathogen interactions has rekindled scientific interest regarding
macrophages. Macrophages display great phenotypic and functional diversity due to their
adaptation to their microenvironment. At the beginning of macrophage studies, researchers used
bone marrow-derived macrophages (BMDM), which are primary macrophages derived from bone
marrow (BM) cells in vitro in the presence of growth factors Macrophage colony-stimulating
factor (M-CSF)4. BM yielded the most macrophages with the best homogeneity but it does not
represent adequate in vivo primary responses. In the past decade, new insights have been expanded
in the origin of tissue-resident macrophages. First, these cells are derived from three progenitors,
including yolk sac macrophages, fetal liver monocytes and circulating monocytes5,6, which
replenish the niches consistently since embryogenesis. Second, even residing in distinct
microenvironments, tissue-resident macrophages have several common features: the ability to
phagocytize pathogens and dying cells, the production of cytokines and chemokines to initiate
immune responses, and the expression of markers such as CD11b, F4/80 and CD64 on the cell
surface of murine tissue-resident macrophages7-10.
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Next to these common features, each tissue resident macrophage population has a unique identity
and function. Interestingly, this functional specialization is dependent on the tissue in which they
reside. For example, tissue resident macrophages located in the brain, called microglia, are small
star-shaped cells and involved in brain surveillance by constantly sensing the cellular environment.
They play important roles in brain development and homeostasis by regulating the synaptic carving
during postnatal development11. Another example is the lung alveolar macrophages which are
responsible for the clearance of alveolar surfactant12. The tissue-specific function of these
macrophages implies that they must have a different functional identity. Furthermore, tissuespecific signals which regulate the expression or activity of signal-dependent transcription factors
(TFs) govern this functional specialization and adapt the core macrophage program by activating
functional modules, which gives macrophages their functional identity. Niche signals from unique
microenvironment also guide the differentiation and development of tissue resident macrophages.

Transcription factors and niche signals involved in tissue-resident macrophage
development
Macrophages form a diverse group of mononuclear phagocytes. Regardless of this heterogeneity,
all macrophage populations share a large transcriptional network and epigenetic landscape. This
core macrophage program is established by a group of lineage-determining TFs which perform a
general role in myelo-monocytic development by determining stem cell fate.

PU.1 is one of the most well studied principal regulators in macrophage development13. PU.1
determines myeloid progenitor fate in a concentration-dependent manner in the process of the early
stages of myeloid cell development. A high level of PU.1 leads to the macrophage development
whereas a low amount of PU.1 is necessary for B cell development14. In the detailed regulation,
3

this concentration-dependent effect can result from the numerous low- and high-affinity PU.1
binding sites present in the genome15. The low-affinity binding sites are only bound by PU.1 when
it reaches a certain threshold concentration. One of the major target genes of PU.1 in macrophage
development is Csf1r, which encodes the receptor for M-CSF (M-CSFR/CD115) and interleukin34 (IL-34). M-CSF is critical in survival, maintenance and proliferation of most mononuclear
phagocytes, whereas IL-34 is specifically required for the development and maintenance of
Langerhans cells and microglia16,17. Together, PU.1 and Csf1r are essential for the formation of
yolk sac macrophages18. Generally, PU.1 regulates tissue-resident macrophage development by
acting as a scaffold for histone modifiers. In addition, many TFs involved in tissue-resident
macrophage development, function and activation perform their function through interaction with
PU.1. For instance, it was shown that c-Jun can enhance the ability of PU.1 to drive expression of
M-CSFR19.

Upon terminal differentiation, MafB expression drives tissue-resident macrophages to exit the cell
cycle20. MafB, synchronizing with c-Maf, desensitize macrophages from the M-CSF-mediated
proliferative effect by blocking the expression of self-renewal genes such as Myc, Klf2 and Klf421.
This acts through direct inhibition of macrophage enhancers, including PU.1. In self-maintaining
tissue-resident macrophage populations, differentiated tissue-resident macrophages can re-enter
the cell cycle by temporarily pausing the inhibition of these enhancers. Contrary to regenerative
processes, dedifferentiation of the tissue-resident macrophages does not happen22. In addition,
MafB plays a key role in F4/80 maturation23 and involves in actin remodeling24.
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Other lineage-determining TFs have been mentioned, including Batf3, Pparg, Irf825. However, it
is not clear whether these factors are essentially required for macrophage development. Moreover,
it is unknown whether macrophages require continuous expression of these factors for their
function, maintenance, or survival. Together, these lineage-determining TFs establish the core
macrophage program, including Cx3cr1, phagocytic receptors, Fcγ receptors (e.g. Fcgr1, encoding
CD64), pattern recognition receptors, Mertk and Adgre1 (F4/80) in the pre-macrophage
commitment by almost all macrophage populations8,25-27. Additionally, these lineage-determining
TFs can shape the epigenome and form an anchor point for signal-dependent TFs accordingly.

Although sharing many similarities, identity and function among all the macrophages are very
diverse and unique for each tissue, implicating that the core macrophage program has to be adapted
in a tissue-dependent manner. According to the niche hypothesis28, the particular niche provides
physical support and nurtures the local tissue resident macrophages through the production of
niche signals. By driving signal-dependent TF expression or activation, cytokines, metabolites,
and cell-cell contacts may all be the niche signals which initiate tissue-specific transcriptional
networks in the pre-macrophages upon emigration29. These local signal-mediated TFs orchestrate
with lineage-determining TFs to fine-tune the core macrophage program and imprint a unique
transcriptional program in the tissue-resident macrophage. This is done through direct activation
of signature genes or by inducing chromatin remodeling which enables signal-dependent TFs to
active signature genes. These signature genes are often necessary for the functional maturation
and/or survival of tissue-resident macrophages to meet the tissue-specific prerequisites.

Peritoneal macrophage
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As a cellular source, scientists have performed studies using peritoneal macrophages and we have
gained a representative portion of the current knowledge regarding macrophage biology, such as
their function, specialization, and development. However, it was described recently the existence
of two resident macrophage subsets present in the peritoneal cavity. According to their size, these
macrophage subsets were labeled LPM and SPM30. In addition to the size, they were designated
by their differential expression of F4/80 and CD11b, where SPMs show F4/80lowCD11blow
phenotype while LPMs express high levels of F4/80 and CD11b. F4/80, a 160 kD glycoprotein
from the epidermal growth factor-transmembrane 7 (TM7) family, is expressed by macrophages
in most organs, and it is not detected on lymphocytes, polymorphonuclear cells, and fibroblasts31.
To be noted, peritoneal eosinophils show low levels of F4/8030 and some macrophage
subpopulations exhibit low levels or do not express F4/80, such as white pulp and marginal zone
splenic macrophages32. CD11b is an integrin that, together with CD18, forms the CR3
heterodimer33, but is not exclusively expressed on macrophages and is found on several others cell
types, including polymorphonuclear cells34, DCs35, and at low levels on B lymphocytes36,37. The
other marker for LPM is ICAM2, a member of the intercellular adhesion molecule (ICAM) family,
while SPMs express low ICAM227. All ICAM proteins are type I transmembrane glycoproteins,
contain 2-9 immunoglobulin-like C2-type domains, and bind to the leukocyte adhesion LFA-1
protein38,39. It mediates adhesive interactions important for antigen-specific immune response,
NK-cell mediated clearance, lymphocyte recirculation, and other cellular interactions important
for immune response and surveillance. It showed that retinoic acid regulates ICAM2 expression
in LPMs40. SPMs phagocytose bacteria and make large amounts of nitric oxide30. Compared to
SPMs, LPMs make much less nitric oxide and have less capacity to phagocytose bacteria. However,
LPMs phagocytose apoptotic cells more effectively41.
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At steady state, LPMs appear to be maintained by self-renewal and independent of
hematopoiesis42,43, whereas SPMs are originated from circulating monocytes. Dates from Schulz
et al. suggest that, in general, F4/80 expression by tissue macrophages correlated with yolk sac
(F4/80high) and not hematopoietic (F4/80low) progenitors44. By using CX3CR1CreRosa26R-FGFP
mice which mark the active and past expression of CX3CR1, the presence of GFP+ cells was found
within DC, SPM, and LPM populations. Conversely, the presence of GFP+ cells was in DC and
SPM pool, but not in the LPM population in the CX3CR1GFP/WT mice. These data indicate that
SPMs are short-lived cells, whereas LPMs have a more dynamic ontogenic relationship with a
CX3CR1+ progenitor. Meanwhile, in chimeric C57BL/6-CD45.2 mice reconstituted with
C57BL/6-CD45.1 BM, the majority of LPMs and SPMs are CD45.1-derived cells, demonstrating
that both macrophage subsets differentiate from BM precursors after irradiation-induced
macrophage ablation43. The other group suggests that Ly6C+ monocytes recruited during
inflammatory conditions could give rise to SPMs30 in a CCR2-dependent manner45.

Data with mice lacking CCAAT/enhancer binding protein (C/EBP)beta also support the idea that
LPMs and SPMs represent distinct ontogenies, because without this transcription factor, there are
no LPMs and increased numbers of SPMs in the peritoneal cavity43. Interestingly, adoptively
transferred SPMs differentiated into LPMs in Cebpb−/− mice. However, in control mice that have
normal numbers of LPMs, only a small frequency of transferred SPMs acquired the
F4/80hiMHCIIlow phenotype of LPMs. These results indicated that SPMs appear to contribute in
only a small way to generate LPMs at homeostasis, but SPMs could maintain the pool of LPMs in
severe situations such as under inflammatory conditions or following radiation ablation43. The
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findings of Yona et al.42 also demonstrated monocyte-derived LPMs presented 8 weeks after
thioglycollate injection. Together with LPMs, a subset of proliferating BM-derived inflammatory
macrophage has also been associated with self-renewal mechanisms during the resolution of
peritonitis induced by zymosan and thioglycollate46. Conversely, LPMs do not seem to contribute
to the SPM pool, even during inflammation.

Intestinal macrophage
Macrophages play a variety of roles to maintain intestinal homeostasis. Like their counterparts in
other tissues, intestinal macrophages are avidly phagocytic. However, intestinal macrophagesmediated phagocytosis in both mouse and man does not cause an overt inflammatory response4751

. Consistent with this role, intestinal macrophages display high expression of genes associated

with phagocytosis, such as Mertk, Cd206, Gas6, Axl, Cd36, Itgav, and Itgb552,53. Integrins αv and
β5 dimerize to form αvβ5, which is involved in efferocytosis54. Notably, Lys2 deletion of integrin
αv in myeloid cells results in the accumulation of apoptotic cells in the intestine55, and Itgb5
deficiency predisposes to increased susceptibility to DSS-induced colitis, highlighting a
particularly important role for this pathway in efferocytosis. The sub-epithelial positioning of
lamina propria (LP) macrophages locates them to control bacteria invasion through epithelial
barrier. In addition, murine studies have shown that they are able to sample luminal bacteria by
transepithelial dendrites, cellular processes that cross the epithelial barrier without perturbing tight
junctions and epithelial integrity and depend on the CX3CL1-CX3CR1 axis56,57.

Though a peripheral monocyte to macrophage differentiation continuum exists in the intestinal LP,
a process which is known as the monocyte “waterfall”9,48, almost all other tissues contain locally
8

maintained macrophage populations that coexist with monocyte-replenished cells at homeostasis.
It was not until recently that Tim-4+CD4+ gut macrophages were found to be locally maintained58,
while Tim-4–CD4+ macrophages had a slow turnover from blood monocytes. TGFβR signaling is
essential for the terminal differentiation of intestinal macrophages. In particular, upregulation of
genes associated with the homeostatic profile of intestinal macrophages, such as Cx3crl, Itgb5,
and Il10 relies on the TGFβ-TGFβR axis52. TGFβ-expressed intestinal macrophages in mucosa
themselves may be important because efferocytosis is known to induce TGFβ expression in
macrophages59 and, at least in man, macrophages may activate TGFβ signaling pathway through
integrin β860. The high expression of CX3CR1 by murine intestinal macrophages and their
positioning adjacent to CX3CL1-producing epithelial cells also imply the possibility of CX3CL1CX3CR1-mediated macrophage differentiation56,57.

In both ulcerative colitis (UC) and Crohn's disease (CD), accumulation of CD14hiCD11chi
monocytes/immature macrophages that come to outnumber CD64+HLA-DRhiCD14lo resident
macrophages48,50,61-63 is one of the features. In contrast to their homeostatic counterparts, these
CD14hi cells in the gut produce pro-inflammatory cytokines and chemokines, such as TNFα, IL1β,
IL6, IL12, and CCL1162,63, display respiratory burst activity64 and respond to commensal bacteria
abnormally. In addition, they express high levels of TREM1, which can potently amplify proinflammatory responses65. Importantly, mucosal healing in IBD patients receiving anti-TNF has
been shown decreased CD14hi cells and increased pro-reparative CD206+ macrophages66.

Gata6
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The GATA zinc finger transcription factors regulate the development and differentiation of several
tissues. Through a conserved Cys-X2-Cys-X17-Cys-X2-Cys zinc finger protein motif, these
factors bind the basic consensus sequence A/TGATA/G. Three members of the family, GATA1,
GATA2 and GATA3, are all expressed in the haematopoietic system and a number of other tissues.
Each appears to have a different function in the haematopoietic system. The other members of
family, GATA4, GATA5 and GATA6, also show a partially overlapping expression pattern in the
heart and the intestinal tract67,68. Murine GATA6 has been reported to be restricted to precardiac
mesoderm, the embryonic heart tube and the primitive gut. It is also expressed in the developing
respiratory and urogenital tracts, arterial smooth muscle cells, the bronchi, the urogenital tract and
the bladder. Overexpression of GATA6 in the cardiac cells at a time when its expression normally
declines (i.e. before the appearance of terminally differentiated markers) results in arrest of
cardiomyogenic differentiation, indicating that the GATA6 gene may act in Xenopus to maintain
the precursor status69. Thus the available data indicates that GATA6 may be important for heart
development. The transcriptional factor Gata6 is specifically expressed by self-renewing
peritoneal macrophages but not by monocytes recently recruited into the peritoneum after
challenge. Gata6 deficiency impairs peritoneal macrophage renewal during steady state and in
response to inflammatory challenge compromising the resolution of inflammation. Gata6 targets
genes involved in cell proliferation since their expression is altered in macrophages from Gata6deficient mice.

Mesothelium
The structure of mesothelium is a single layer of thin plate-like cells. The squamous mesothelia
are polarized with their apical microvilli and cilia-rich surfaces toward the coelomic space70,71.
10

Tight junctions located on the lateral aspect of the cell maintain apical/basal polarity and create a
diffusion barrier between the coelomic space and the submesothelial connective tissue of the organ
or body wall. Cytokeratins (mostly subtypes 8, 18, and 19) provide structural support and Ecadherin confers further cell-cell adhesion72,73. A basement membrane is produced by and
underlies the mesothelium separating it from the sub-mesothelial connective tissue space. In
mammals, separation of the common embryonic coelom gives rise to pericardial, pleural and
peritoneal cavities. To further subdive, mesothelial cells lining the organs are referred to as visceral
mesothelia while parietal mesothelia cover the organs cavities/body walls. Visceral mesothelium
covering the heart is referred to as the epicardium while pleural mesothelium covers lungs. Serosal
mesothelium covers the organs of the alimentary canal within the abdominal cavity/coelom.
Despite the multiple names, mesothelium has a relatively consistent structure in each of the
coelomic cavities.

The most conspicuous function of mesothelia in the adult is to produce a non-adhesive surface
which allows frictionless movement of the organs within the coelomic cavity. The secretion of an
apical glycosaminoglycan layer and production of a small amount of circulating coelomic fluid to
provide lubrication are the key for this dynamic movement74,75. Submesothelial lymphatic vessels
connect with gaps in the mesothelial monolayer called stomata on the surface of the diaphragm70.
Mesothelium not only regulates ionic and protein composition of coelomic cavity fluid but also
the passage of inflammatory cells76,77. Additionally, mesothelium is crucial to the injury response
and is thought to both prevent and promote scarring depending on the injury and to promote
neovascularization78-80. These and many other studies have provided growing evidence for the
dynamic role of mesothelium in both normal and abnormal physiologic states in the adult81.
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Msln and Mucin 16
Msln is a glycophosphatidylinositol (GPI) –linked cell-surface glycoprotein. It is synthesized as a
71-kD precursor protein and is then cleaved by the endoprotease furin to release the secreted Nterminal region, called megakaryocyte potentiating factor (MPF), whereas the 41-kD mature Msln
remains attached to the membrane82,83. The remaining GPI-linked mature Msln can also be shed
from the cell through the action of the tumor necrosis factor α–converting enzyme protease84. The
normal physiologic distribution of Msln identifies it as a differentiation factor for mesothelial cells,
but the biologic role that Msln plays in these cells remains unclear. Database searches reveal that
Msln is remotely homologous to two inner ear proteins of unknown structure and contains no
conserved consensus domains85. Three-dimensional structure prediction programs have
determined that Msln consists of a superhelical structure with armadillo-type repeats86. No crystal
structure has yet been determined for the whole protein, but the structure of an N-terminal fragment
bound to a Fab of the SS1 antibody has been obtained87. Furthermore, Msln knockout mice grow
and reproduce normally and have no detectable phenotype88.

Msln is expressed by many solid tumors, with particularly robust expression in mesothelioma,
epithelial ovarian cancer, and pancreatic adenocarcinoma89-92. Higher expression of Msln has been
correlated with poorer prognosis for patients with ovarian cancer93, cholangiocarcinoma94, lung
adenocarcinoma95, triple-negative breast cancer96, and resectable pancreatic adenocarcinoma97. In
the neoplastic setting, Msln is known to bind to the ovarian cancer antigen Muc16 (cancer antigen
125)98. Muc16 is a membrane spanning mucin that is expressed on ovarian, endometrial, tracheal,
and ocular surface epithelial cells. This mucin is initially expressed on the surface and then shed
in the extracellular milieu following proteolytic cleavage. The two proteins are frequently
12

coexpressed, and binding of Msln and Muc16 has been shown to induce cell-to-cell adhesion in
these cell types99. Muc16 expressed on cancer cells can also facilitate cancer cell attachment to the
Msln-expressing serosal surfaces in the pleura and peritoneum, possibly contributing to peritoneal
seeding and metastatic spread. In addition, signaling mediated by Msln and Muc16 binding has
been reported to increase cellular resistance to anoikis100, upregulate matrix metalloproteinases
important in cellular invasion and metastasis101, and induce secretion of autocrine growth factors
by constitutively activating nuclear factor kappa B (NF-κB)102,103. However, it seems that Msln
expression may also trigger signaling events independent of Muc16 binding90. The exact
mechanics of these pathways and how Msln interacts with components of the tumor microenvironment, including stromal cells, the extracellular matrix, and immune-cell populations, are
not known.

Why Msln, a glycoprotein normally restricted to serosal cells of the pleura, peritoneum, and
pericardium, is expressed in a wide variety of adenocarcinomas is not clear at this time. However,
regulation of Msln expression in tumors has been assessed in several studies and seems to be celltype specific. At the epigenetic level, it was found that hypomethylation did not correlate with
Msln expression in ovarian or endometrial cancer specimens or in mesothelioma104. However,
hypomethylation of the promoter was noted in Msln-expressing pancreatic cancer specimens, and
treatment of a nonexpressing pancreatic cancer cell line with demethylating agents could induce
expression of Msln, suggesting that epigenetic mechanisms may regulate Msln expression in this
cell type89. Transcription of Msln is driven by a TATA-less promoter located upstream of the
transcriptional start site. Enhancers responsible for initiating strong expression in normal serosal
cells and cancers derived from them (eg, mesothelioma and ovarian cancer) are unknown. Cancer-
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specific ectopic upregulation in pancreatic and cervical cancers has been attributed to the
transcriptional enhancer factor 1 (TEF-1) transcription factor binding to a conventional MCAT
sequence within an upstream enhancer region called CanScript. However, TEF-1 expression itself
is necessary but not sufficient to induce Msln expression, suggesting an unknown cofactor is also
required105. Similarly, the yes-associated protein 1 (YAP1) transcription factor binds to an SP-1
motif within the CanScript and is also required but insufficient for MSLN expression106. Further
study will be required to delineate this mechanism. More recently, it was discovered that Msln is
reciprocally regulated at the post-transcriptional level by mIR-198 as part of a feedback loop that
involves NF-kB and the homeobox transcription factors octamer transcription factor 2 (OCT-2),
pre–B cell leukemia homeobox 1 (PBX-1), and valosin-containing protein107.

Recently more researches delineate the role of Msln in non-tumorigenesis condition. One group
determined that Msln facilitates both TGF-β1–induced activation of activated portal fibroblasts
(aPFs) and FGF-induced proliferation of aPFs108. And the mice lacking Muc16 had similar results
in the murine liver fibrosis model. They also detected a similar upregulation of Msln+ aPFs in
patients with biliary fibrosis of different etiologies. The other group found up-regulation of Msln
in both human and murine peritoneal adhesions, which indicated that Msln expression correlated
to injury-induced inflammation109. Upon injury, many activated fibroblasts share similar
mesothelial markers. And one of the studies demonstrate that human Muc16 inhibits the cytolytic
functions of both human and murine NK cells and macrophages to a similar degree. These studies
are important steps in using mouse models to delineate the immuno-regulatory roles of
Msln/Muc16 that provide immune protection to ovarian and other epithelial tumors. Several recent
studies highlight the need to investigate the effects of Muc16 on immune cells110. Most importantly,
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the correlation of decreased therapeutic responses of farletuzumab and amatuximab in patients
with higher circulating levels of Muc16 and the ability of this mucin to perturb interactions
between therapeutic antibodies and Fc-γ receptors are raising the possibility that Msln/Muc16 and
other mucins could influence the success of some anti-cancer immunotherapies111.

Model of peritonitis
Infectious peritonitis triggered by the injection of pathogens into the peritoneal cavity has been
used as a model to study innate immunity during acute inflammation since the time of Mechnikov.
However, infectious peritonitis models are hard to control because the exact time course of the
inflammatory response

depends

on

both

the pathogenicity and growth

rate of the

specific microorganisms used and the magnitude and efficacy of the host immune responses.
Experimental animal models can be used to study specific aspects of the pathophysiology of
peritonitis as it presents in the clinic, and these models provide platforms for illuminating the
general mechanisms of inflammation and testing novel anti-inflammatory strategies. For instance,
the cecal ligation and puncture (CLP) model mimics the polymicrobial sepsis112.

The intraperitoneal injection of a wide range of irritants leads to an acute inflammatory response
that peaks within hours, including thioglycollate broth113 and inflammatory cytokines114. Injection
of zymosan, the insoluble polysaccharide cell wall component derived from Saccharomyces
cerevisiae, is a popular self‐resolving model of peritoneal inflammation in mice, which induced
all the hallmarks of acute inflammation, including pain, leukocyte infiltration, and synthesis of
inflammatory mediators including leukotrienes and prostaglandins115. It provides a direct
analog of many of the features observed in in vitro zymosan-treated macrophages. Macrophage
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recognition of unopsonized zymosan in vitro is β‐glucan receptor dectin‐1 dependent116; whereas
collaborative signaling from TLR2 by an MyD88‐dependent signaling pathway induces the
generation of inflammatory mediators. In vivo Peritonitis experiments also show dectin-1
recognized zymosan and controlled fungal infection117.

Zymosan-induced peritonitis model has several advantages over other reagents. First, the mild‐to‐
moderate severity of the injury (which can be varied with the dose of zymosan) means that
inflammation self‐resolves within 48 to 72 h, mimicking the normal inflammatory response of an
immunocompetent individual. Second, the model allows collection of a reasonable amount of
exudate for analyzing multiple inflammatory mediators. Third, injection into a serosal cavity
means that leukocytes exit from the site of inflammation by way of their natural conduits to the
draining lymph node118,119. Finally, this model enables a wide range of researches due to the
relative technical simplicity and reproducibility. In addition, because peak neutrophil levels occur
within 3-4 h of a 2x106 zymosan particles injection, it is convenient to generate and analyze data
within a short time frame.

Models of colonic injury
The tube-shaped colon is composed of several layers. The inner-most layer is the epithelial layer,
which separates the contents of the lumen from the host. The mesenchymal layer which includes
neuronal, stromal, and hematopoietic cells is adjacent and supporting the epithelial layer. Together,
these two layers are called the mucosa. The next radial layer is the submucosa composed of
muscularis propria, including the circular and longitudinal muscle layers. The outer-most radial
layer of the colon is the single-mesothelial-cell serosal layer.
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The colonic epithelium is composed of many invaginations called crypts of Lieberkuhn. The
highly proliferative epithelial stem cells reside at the base of the each crypt and divide to produce
progenitors and more stem cells. The progenitors divide and differentiate into absorptive
enterocytes, secretory goblet cells, or enteroendocrine cells. The mature epithelial cells move up
from the crypt to reach the top and undergo apoptosis. Their migration away from canonical Wnt
signaling that enriches at the base of the crypts drives the differentiation of progenitors and benefits
the maintenance of homeostasis; however, during inflammation or infection, the compromised
barrier function drives mucosal repair through the overwhelming epithelial renewal. Various injury
models in mice have been used to study the mechanisms for colonic immune-epithelial interaction
after injury and to gain novel treatments to stimulate intestinal repair.

Many animal models of inflammatory bowel disease (IBD) recapitulate certain aspects of the
human disease120. For instance, administration of chemicals like dextran sodium sulfate (DSS)121
or 2,4,6-trinitrobenzene sulfonic acid (TNBS)122 leads to significant epithelial damage and
inflammation. Other models of IBD include cell transfer models (adoptive transfer of
CD4+CD45RBhigh T cells)123 and genetic models (e.g. IL-2 or IL-10 KO mice). There are other
models of intestinal epithelial damage such as radiation, ischemia/reperfusion, and Clostridium
difficile infection that all lead to intestinal inflammation and/or loss of crypts. Given IBD results
from abnormal crosstalk between genetics and the environment, these models help identifying
important mediators of inflammation such as cytokines and bacterial products.
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Our lab has used the murine colonic biopsy injury system to study mechanisms of epithelial
repair124. To create mucosal wounds, we insert a pair of forceps into the colon of an anesthetized
mouse and remove around 300 crypts and the mesenchymal layer but not cause perforation. This
system is ideal for studying the mechanisms of temporal and spatial mucosal repair. This system
can be used to study mice that are genetically deficient for genes that are known to be important
in mucosal repair and discover novel genes important in mucosal repair.
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CHAPTER TWO

Mesothelial niche Msln and mucin 16 shape tissue resident macrophage differentiation
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Chapter 2: Abstract
The local cellular environment of each tissue is thought to play a role in shaping resident
macrophage differentiation state. In the peritoneal cavity, dietary retinoic acid has previously been
shown to polarize macrophages in this location through the reversible induction of a transcription
factor which defines LPM identity, Gata6. We hypothesized that local factors in the peritoneum
could also support tissue-specific differentiation of macrophages. We found that soluble proteins
from the peritoneum upregulated Gata6 expression in stimulated LPMs. We investigated
mesothelial cells because of their known function in secreting factors into the peritoneal fluid and
their interactions with resident immune cells. Analysis of their global gene expression highlighted
Msln and its binding partner Muc16 as candidate ligands to regulate Gata6 expression in LPMs.
We found that mice deficient for either of these molecules showed diminished Gata6 and F4/80
positive LPMs in homeostasis. Pleural cavity macrophages, similarly to LPMs, display lower
Gata6 and F4/80 expression in Msln-/- and Muc16-/- mice, suggesting that Msln and Muc16 exhibit
generalizable effects across cavities derived from the intraembryonic coelom. Compared to wildtype recipient mice, lethally irradiated Msln-/- and Muc16-/- mice reconstituted with wild-type bone
marrow have lower Gata6 and F4/80 expression in LPMs and pleural cavity macrophages.
Similarly, during the resolution of zymosan-induced inflammation, repopulated LPMs expressed
diminished Gata6 and F4/80 in the absence of Msln or Muc16, suggesting these ligands have the
extrinsic impact on resident macrophage differentiation. Overall, we found novel tissue-specific
factors that regulate differentiation of resident macrophages in mesothelium lined cavities.
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Chapter 2: Introduction
Macrophages are members of the mononuclear phagocytic system that reside in every organ3,125,126.
These cells play important roles in a variety of important processes including the initial control of
infection and response to tissue damage. To execute their functions in the context of specific organs,
tissue resident macrophages (TRMs) must adapt to their local environment27,127-130. The
specialization of TRMs occurs by the instruction of specific transcription factors that are induced
by factors within the microenvironment131. TRM phenotypes can be defined by a combination of
multiple transcription factors that control the functional programs of these cells.

In the peritoneal cavity, LPMs are the dominant TRMs that functionally mediate type 2 immunity,
facilitate the tissue repair of the mesothelium, and protect against peritoneal fibrosis30,132,133. LPMs
require the induction of transcription factors, including C/EBPβ43 and Gata640,134,135. Gata6
deficiency results in dysregulated peritoneal macrophage proliferative renewal during homeostasis
and in response to inflammation, which is associated with delays in the resolution of
inflammation135.

Previous studies have shown that local factors play key roles in promoting the ontogeny and
phenotype of TRMs133,136. Among factors known to be important for LPM function40,134,135,137,
omentum-derived retinoic acid (RA) induces Gata6 expression in LPMs40,127 which in turn
regulates gene expression of factors that define peritoneal macrophages. It is still unclear whether
RA is the sole local factor that regulates Gata6 expression in LPMs.
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Mesothelial cells are important tissue factor producers due to their immediate proximity to the
serosal cavities. In addition to roles in the pleura and pericardium70,138, mesothelial cells line the
entire peritoneal cavity and produce a protective, non-adhesive barrier against physical and
biochemical damage from infection and surgery76,77. Mesothelial cells play key roles in fluid
transport and inflammation, as reflected in their expression of proteins such as solute transporters,
adhesion molecules, cytokines, growth factors, and reactive oxygen species. These cells also
express a wide range of lineage markers, including the adhesion protein mesothelin (Msln)139 and
its binding partner mucin 16 (Muc16)140.

We hypothesize that mesothelial cells can communicate with LPMs to affect their differentiation
state and function through modulation of Gata6 expression. We found that a high molecular-weight
complex in the peritoneal fluid contains the secreted proteins, Msln and Muc16, which preserve
Gata6 expression in isolated and cultured LPMs. We further identified that Msln and Muc16 play
key roles during in the extrinsic control of Gata6 expression in LPMs and pleural macrophages
during homeostasis and injury. Collectively, these data delineate a role for soluble, microenvironmental factors in regulating tissue macrophage identity.

Chapter 2: Methods and Materials
Methods
Mice
C57BL/6J (CD45.2) and B6.SJL (CD45.1) mice were obtained from Jackson Laboratories. Msln–
/– 88

and Muc16–/– mice141 on the C57BL/6 background were provided by Dr. Ira Pastan (National

Cancer Institute, USA) and Dr. Robert C. Bast (MD Anderson Cancer Center, USA), respectively.
Lyz2 Cre x Gata6flox/flox and Gata6flox/flox littermate controls were provided by Dr. Gwendalyn J.
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Randolph and generated as previously described134. All mice were used for experiments were
between 8 and 12 weeks of age unless otherwise stated and were maintained in one of two specific
pathogen-free barrier facilities. Sex-matched littermates were used for experiments whenever
possible, although in some cases mice from multiple litters were used in a single experiment. All
animal experiments were approved by the Animal Studies Committee of Washington University
in St. Louis.

Leukocyte Collection
Peritoneal and pleural cells were collected from body cavities by lavage with 0.5% BSA and 2
mM EDTA in 1x PBS (FACS buffer). Spleen and Peyer’s patches were excised, placed in sterile
FACS buffer, and finely minced. Cellular suspensions were passed through a 70 μm cell strainer
before analysis. If lysis of red blood cells was necessary, cell suspensions were treated with Red
Blood Cell Lysis Buffer (Sigma) according to the manufacturer’s protocol. Live cells were counted
with Countess II FL cell counter (Invitrogen) using a Trypan Blue stain for dead cell exclusion.

Flow Cytometry
Cells were stained for surface markers by blocking with α-CD16/32 (clone 2.4G2, Tonbo) for 10
minutes at 4 ⁰C followed by staining for 20 min at 4 ⁰C before running on a flow cytometer in
FACS buffer. Cells which were to be stained intracellularly were first stained for surface markers
and then were stained as indicated by the FoxP3/Transcription Factor Staining Buffer set
(eBioscience). In brief, surface stained cells were fixed, permeabilized, and stained with either
Gata6 or Ki67 for 20 min at 4 ⁰C, followed by washing once in 1x Perm/Wash buffer and then
resuspension in FACS buffer before flow cytometric analysis.

23

Single-cell preparations were stained with antibodies to the following markers: anti-B220 (clone
RA3-6B2; BioLegend), anti-CD3 (clone 17A2; BioLegend), anti-CD4 (clone RM4-5; BioLegend),
anti-CD5 (clone 53-7.3; BioLegend), anti-CD8a (clone 53-6.7; BioLegend), anti-CD11b (clone
M1/70; BioLegend), anti-CD11c (clone N418; BioLegend), anti-CD19 (clone 1D3; BioLegend),
anti-CD45.1 (clone A20; BioLegend), anti-CD45.2 (clone A104; BioLegend), antiCD102/ICAM2 (clone 3C4; BioLegend), anti-CD105 (clone MJ7/18; BioLegend), anti-CD115
(clone AFS98; BioLegend), anti-CD117 (clone 2B8; BD), anti-CD135 (clone A2F10.1; BD), antiCD138 (clone 281-2; BioLegend), anti-F4/80 (clone BM8.1; eBioscience), anti-Gata6 (clone
D61E4; Cell Signaling Technologies), anti-GL7 (clone GL7; BD), anti-MHC-II (clone
M5/114.15.2; BioLegend), anti-Ki67 (clone SolA15; eBioscience), anti-Ly6C (clone HK1.4;
BioLegend), anti-Ly6G (clone 1A8; BioLegend), anti-GPM6a (clone 321; MBL), anti-NK1.1
(clone PK136; Tonbo), anti-Pdpn (clone 8.1.1; BioLegend), anti-SiglecF (clone E50-2440; BD),
anti-streptavidin (Thermo), anti-TER119 (clone TER-119; BioLegend), and anti-Tim4 (clone
RMT4-54; BioLegend).

In experiments to assess cell death, cell suspensions were washed once in 1x PBS, resuspended in
Annexin binding buffer, and stained with FITC-conjugated Annexin V and Propidium Iodide as
per the manufacturer’s instruction (BD). Flow cytometry was performed on FACS Canto II, LSR
Fortessa, LSR Fortessa X20, or LSR II instruments (BD). FlowJo software (Treestar) was used for
analysis.
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All cells were first gated on a FSC/SSC gate and a FSC-W/FSC-A singlet gate. Peritoneal and
pleural macrophages were gated as CD115+ CD11b+ and then divided into ICAM2+ MHC-IIlo large
macrophages or ICAM2- MHC-II+ small macrophages. Peritoneal eosinophils were gated as
Siglec-F+ CD11bint, and peritoneal B cells were gated as CD115- CD19+ MHC-II+. In the spleen
and Peyer’s patches, B cells were gated as B220+ CD3-, plasma cells as B220+ GL7+, and germinal
center B cells as B220- CD138+. CD4+ T cells were gated as CD3+ CD4+, and CD8+ T cells as
CD3+ CD8+. NK cells were gated as NK1.1+ CD3-, and neutrophils were gated as Ly6C+ Ly6G+.
Red pulp macrophages were gated as F4/80hi CD11blo MHC-IIlo CD11clo. Common monocyte
precursor (cMoP) cells were gated as cKitlo Flt3- CD115+ Ly6chi CD11b+ CD11c- Ly6G-.

LPM and BM-Monocyte Sorting
Large peritoneal macrophages were sorted from peritoneal exudate cells using a CD11b+ ICAM2+
F4/80+ gating strategy. Monocytes were isolated from red blood cell lysis buffer–treated bone
marrow cell suspensions using immunomagnetic depletion of T cells, B cells, DCs, granulocytes
and natural killer cells with anti-rat immunoglobulin-coated magnetic beads (Invitrogen) at a 7:1
bead-to-cell ratio. Immunomagnetic beads were prepared by incubation with rat anti-mouse
monoclonal antibodies conjugated against the lineage defining markers CD3, CD19, CD105,
TER119 and Ly6G. Lineage depleted cell suspensions were sorted for monocytes using a CD11b+
CD115+ Flt3- cKit- Lineage- gating strategy. Monocyte preparations had a purity of greater than
90% as measured by post-sorting flow cytometry. Cells were sorted on a FACS Aria Fusion or an
Aria II flow cytometer (BD).

Bone-marrow-derived Macrophage Culture
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Femurs and tibia were removed from CD45.1 wild-type or CD45.2 wild-type, Msln-/-, or Muc16-/mice and flushed with FACS to remove the bone-marrow. Bone-marrow cells were pelleted,
resuspended with RPMI (Gibco) + 10% FBS + 20ng/mL M-CSF (Biolegend), seeded onto
untreated petri dishes, and cultured for 6 days. Cells were removed mechanically by scratching
into 1x PBS before adoptive transfer experiments.

Adoptive Transfer
For the transfer experiment, 2X105 cells were injected intraperitoneally into the recipient mouse
and collected 12 days later for flow cytometric analysis.

Peritoneal Lavage Preparation and Treatment on LPM
Mice were injected intraperitoneally with 2 ml of DMEM (Sigma) supplemented with 1%
penicillin–streptomycin (Sigma). After gently massaging the mouse for 30 seconds, the lavage
fluid was removed, centrifuged at 1500 rpm and 4˚C for 5 min, and the cell-free supernatant was
collected for further experiments. Lavage fluids were boiled to denature proteins by incubation at
95˚C for 10 min.

Ex Vivo Stimulation
For experiments requiring culturing, 200,000 sorted LPMs were seeded onto tissue-culture treated
96-well plates and maintained in DMEM + 1% penicillin-streptomycin. Cells that were to be used
as no-culture controls were fixed immediately after sorting using 4% (v/v) paraformaldehyde and
kept until analysis. Cells in experimental groups were cultured for 24hrs before harvesting for
protein analysis or for 6hrs before qRT-PCR analysis. In experiments with the blockade of Msln,
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LPMs were treated with un-fractioned peritoneal lavage fluid plus either 25μg/ml Msln blocking
or isotype control antibodies (Antibody 1: MBL and Antibody 2: Abbiotec) for 24 hours before
collection. Amicon Ultra-15 100K MWCO (Millpore) was used to size fractionate the peritoneal
lavage fluid according the manufacturer’s protocol.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
RNA was isolated from sorted LPMs with the NucleoSpin RNA kit (Macherey-Nagel), and cDNA
was synthesized with iScript cDNA kit (Bio-Rad). qRT-PCR was performed with TB Green qPCR
premix (Clontech) using an Eppendorf Master-cycler. Relative expression levels were normalized
to Hprt which was expressed at similar levels in all samples. The following primers were used:
Hprt, forward 5′-TCAGTCAACGGGGGACATAAA-3′, reverse 5′-GGGGCTGTACTGCTTA
ACCAG-3′; Gata6 forward 5’- TTGCTCCGGTAACAGCAGTG-3’ reverse 5’- GTGGTCG
CTTGTGTAGAAGGA-3’. Cebpb forward 5’-GGAGACGCAGCACAAGGT-3’ reverse 5’AGCTG CTTGAACAAGTTCCG-3’; Bhlhe40 forward 5’- CGTTGAAGCACGTGAAAGCA-3’
reverse 5’- TCCCGACAAATCACCAGCTT-3’; Rarb forward 5’- ACATGATCTACACTTGC
CATCG-3’ reverse 5’- TGAAGGCTCCTTCTTTTTCTTG-3’; Nfe2 forward 5’- TCCTCAGCA
GAACAGGAA CAG-3’ reverse 5’- GGCTCAAAAGATGTCTCACTTGG-3’.

Primary Peritoneal Mesothelial Cell Isolation
Mesothelial cells for RNA sequencing were isolated from 8 to 12 week-old wild-type or Msln–/–
mice using a previously described protocol142. Briefly, mice were sacrificed, and their peritoneal
cavities were exposed. The peritoneal cavities were washed with injecting 10 ml of 1x PBS
(Sigma) via a syringe equipped with a 25G×5/8″ needle (BD). After gently shaking for 30 seconds,
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the fluid was removed and discarded. The peritoneum was filled with 5 ml of 0.25%
Trypsin/EDTA solution (Gibco). The corpse was then maintained at 37°C for 20 min in a tissueculture incubator before removal of the fluid. The detached cells were pelleted by centrifugation
at 300×g for 10 min and resuspended in FACS buffer. The mesothelial cells were sorted from the
cell suspension as CD45- PDPN+ GPM6a+ cells into DMEM + 10% FBS on a FACS Aria II flow
cytometers (BD).

RNA-sequencing and Analysis
Primary mesothelial cells were collected from 10 week old mice as mentioned above. Total RNA
was extracted using NucleoSpin RNA kit (Macherey-Nagel). RNA-sequencing libraries from
peritoneal mesothelial cells were generated and sequenced at the Genome Technology Access
Center (GTAC) at Washington University. Pooled libraries were sequenced on an Illumina HiSeq
2500 using 1x50 single end sequencing. Transcript abundance was estimated using Kallisto
software
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and the Gencode M14 annotation (GRCm38.p5 assembly). Transcript abundances

were summarized at the gene-level using the R package tximport (Soneson), and then preprocessed and normalized using packages edgeR and Limma (Robinson, Ritchie). Raw sequence
data from published studies of murine large peritoneal macrophages and inguinal adipose tissue
was downloaded from the NCBI Short Reads Archive. Transcript abundance was estimated and
summarized in an identical fashion. Differential expression testing was performed with Limma,
using cut-off values 10-4 for adjusted p-value and 4 for log2 fold change.

Msln and TNFα ELISA
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Peritoneal lavage was prepared from naïve wild-type and Msln-/- mice as described above and
measured for Msln concentration using a Msln ELISA kit (Abcam) according to manufacturer's
instructions. . For TNFα ELISA, peritoneal exudate cells were prepared from naive wild-type and
Msln-/- or Muc16-/- mice. 200,000 cells were seeded onto tissue-culture treated 96-well plates and
stimulated with 1μg/ml LPS in DMEM + 10% FBS for 24 hours. Supernatant was measured for
TNFα concentration using a TNFα ELISA kit (Biolgend) according to manufacturer's instructions.
The signals were measured by Cytation 5 (Biotek).

In situ Hybridization
Tissues were fixed in 4% (v/v) paraformaldehyde at 4⁰C for 18 to 24 hours, dehydrated with 20%
sucrose in 1x PBS, and embedded in OCT (Sakura Finetek). Tissue sections were cut at a thickness
of 5 µm and were used for RNAscope based in situ hybridization according to the protocols
recommended by the manufacturing company (Advanced Cell Diagnostics). The RNAscope
probes used were Mm-MSLN and Mm-MUC16.

Zymosan-induced Peritonitis
Peritonitis was induced by intraperitoneal injection of 2x106 zymosan particles (Sigma). Peritoneal
exudate cells were collect by peritoneal lavage as described earlier after 3 hours or 7 days as
indicated.

Bone Marrow Chimeras
Recipient CD45.1 or CD45.2 mice were lethally irradiated with a single dose of 1050 rads from a
gamma irradiator and after an overnight rest period were reconstituted intravenously with 10
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million bone-marrow cells from the indicated donor animals. Mice were allowed to reconstitute
their hematopoietic compartment for at least 8 weeks before experimentation.

Statistical Analysis
All data are from at least two independent experiments, unless otherwise indicated. Pairwise
comparison data were analyzed by unpaired two-tailed Mann-Whitney U-tests. Statistical
significance between multiple groups was evaluated by one-way ANOVA followed by Tukey’s
multiple comparisons post-hoc test. Data analysis was conducted in Prism 8 (GraphPad Software,
Inc.). A p-value of less than or equal to 0.05 was considered significant.

Data Availability
The data that support the findings of this study are available from the corresponding author upon
request. The RNA sequencing data are deposited under the GEO repository accession codes GSE
129391.

Chapter 2: Result
Mesothelium-derived protein Msln and Mucin 16 sustains Gata6 expression in LPMs
LPMs require Gata6 expression for maintenance of their function40,134,135. Addition of retinoic acid
to LPMs in vitro can stimulate a detectable increase in Gata6 expression in LPMs40,127. Using this
experimental system, we cultured sorted LPMs (FSClntCD11b+ICAM2+F4/80+) in serum-free
media and found that Gata6 protein expression in LPMs was not maintained after 24 hours of
culture (Fig 1A-C). Under these experimental conditions, we found that additional treatment of
LPMs with peritoneal lavage fluid from wild-type (WT) mice could partially preserve Gata6
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protein levels in LPMs. This activity appeared to be due to protein factor(s) as heat denaturation
diminished the effect of the peritoneal lavage fluid in this assay. The effects of the peritoneal
lavage fluid similarly affected Gata6 mRNA expression after 6 hours of culture (Fig 1D).

Due to their immediate proximity to the peritoneal cavity, we propose that mesothelial cells can
produce and secrete proteins into the peritoneum144 to maintain Gata6 expression by LPMs. We
used comparative transcriptomics to identify secreted factors that were specifically and highly
expressed in primary mesothelium. We performed bulk RNA-sequencing of mesothelial cells
from 10 week old healthy mice. Using publicly available data-sets from healthy mice, we identified
genes that were expressed at significantly greater levels in mesothelial cells as compared to two
other peritoneal cell types, adipocytes and LPMs127,145. Transcripts from 315 genes were
significantly enriched in mesothelial cells using cut-off values 10-4 for adjusted p-value and 4 for
log2 fold change. As expected, this list included known mesothelial markers including Wt1 and
Gpm6a. Two genes, Msln and Muc16, were among the most highly enriched genes that were
predicted to be secreted from mesothelial cells (Fig. 1E and Supplementary Fig 1A).

One candidate, Msln was of interest as it is specifically expressed by mesothelial cells146 and not
immune cells in the peritoneal cavity (Supplementary Fig 1B, C), and it has been shown by
previous work to be a secreted protein147-150. In addition, in vivo and in vitro tools have been
developed previously to study its function151. Using the model of cultured LPMs as above, we
blocked Msln function by mixing the lavage fluid from WT mice with Msln blocking antibodies.
We used two antibodies that recognize different epitopes of Msln and both antibodies inhibited the
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maintenance of Gata6 expression in isolated and cultured LPMs while isotype controls had no
detectable effect (Fig. 1F, G).

We next evaluated the expression of Msln. By ELISA, we detected Msln protein in peritoneal
lavage fluid of WT but not Msln-/- mice (Fig. 1H). Because a mature 30kD Msln protein has been
described to function in a complex with other proteins such as Muc16 (MW >250kDa), we
performed size selection on the peritoneal lavage fluid from WT mice and found proteins in a
fraction >100kD contained the majority of Msln while the smaller sized fraction (<100kD)
contained lower levels of Msln. We found that the >100kDa fraction contained the activity required
to preserve Gata6 expression at an RNA and protein level (Fig. 1I, J). Muc16 has been proposed
to be a co-factor for Msln in cancer cells 98,152 and is known to have a secreted form 153. Similar to
Msln, it is specifically expressed by mesothelial cells but not immune cells (Supplementary Fig
1D, E). These data create the hypothesis that Msln and Muc16 produced by mesothelial cells are
important local factors for the preservation of the expression of the transcription factor Gata6 in
LPMs, suggesting a possible role that is similar to a previously described role for retinoic acid
40,127

. Our results show that proteins (Msln and Mucc16) in the peritoneal fluid can maintain Gata6

expression in ex vivo cultured LPMs.

Msln

-/-

mice have lower expression of specific markers of LPMs

We analyzed LPMs and other immune cells in the peritoneal cavities in Msln-/- and Msln+/+
littermate control adult mice. The number of LPMs was similar in Msln-/- mice and controls
(Supplementary Fig 2A). However, the Gata6 and F4/80 levels of expression of LPMs isolated
from Msln-/- mice were lower than controls (Fig 2A-E). Macrophages in the lung pleural space of
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Msln-/- mice also showed lower levels of Gata6 and F4/80 expression as compared to littermate
controls (Fig 2F-H). To determine if Msln has an effect on peritoneal cavity inflammation, we
injected zymosan into the peritoneal cavity of mice which induces neutrophil infiltration in WT
mice within 3 hours46. Msln-/- mice had increased neutrophil infiltration in response to zymosan
injection as compared to littermate controls and this effect was comparable to the effects of
zymosan injection into Gata6 conditional knockout in macrophages (Gata6f/f, LysM-Cre) mice135
(Fig 2I). We also used zymosan treatment to stimulate the loss of macrophages in the peritoneal
space and to study macrophage repopulation from blood derived monocytes154. As expected, >99%
of LPMs were no longer detected in the peritoneal lavage of treated WT and Msln-/- mice after 3
hours of zymosan treatment
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. We found that in zymosan treated Msln-/- mice, the LPMs that

repopulated the peritoneal cavity had a lower proportion of Gata6-positive, F4/80-positive cells as
compared to similarly treated WT littermates (Fig 2J-L). This finding suggests that Msln can
influence TRM identity in mesothelium-lined compartments at both the steady state and during
inflammation.

To investigate the effects of Msln on LPMs during development, we analyzed immune cells
from the peritoneal cavity of two week old littermate WT and Msln-/- mice. Surprisingly, the
expression of F4/80 and Gata6 in LPMs from Msln-/- mice was comparable to WT controls
(Supplementary Fig 2B, C). The percentage of Gata6 and F4/80 low LPMs in two-week old Msln/-

mice was also comparable to controls, suggesting that Msln affects LPM identity after this

developmental time period. Using LPMs in adult Msln-/- naïve mice, we found no defects in LPM
proliferation (Ki67+) or cell death (AnnexinV+PI+) (Supplementary Fig 2D, E). Amongst the
other immune populations of peritoneal exudate cells, splenocytes, and lymphoid cells in Peyer’s
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Patches, we observed no difference in the abundance of these cells in Msln-/- mice (Supplementary
Fig 2F-J). These results were replicated in a second facility with a distinct microbiome155,
suggesting that this phenotype is not dependent on differences in gut microbes (Supplementary
Fig 2K). We also examined Gata6 and other LPM-related gene expression in LPM by qRT-PCR
and found that Msln deficiency affected not only Gata6 but also Bhlhe40, a tissue-specific
transcriptional regulator of LPM proliferation156 (Supplementary Fig 2L). Overall, we found that
adult Msln-/- mice have abnormal TRMs in mesothelium-lined compartments and these cells
express lower levels of identity defining markers Gata6 and F4/80.

Msln acts extrinsically on Gata6 expression during TRM differentiation in bone marrow
chimeras
Based on these findings, we hypothesized that Msln produced by mesothelial cells acts locally in
the peritoneal cavity to influence Gata6 expression in LPMs and that continuous exposure of LPMs
to Msln is needed for optimal expression of Gata6. We first excluded a developmental role for
Msln in bone marrow (BM), as both WT and Msln-/- mice had similar numbers of common
monocyte progenitors (cMoPs)157 (Fig 3A). We next reconstituted irradiated WT and Msln-/CD45.2 mice with WT CD45.1 bone marrow in order to determine extrinsic versus intrinsic effects
of Msln. The CD45.1 macrophages expressed less Gata6 in Msln-/- recipient mice as compared to
WT recipients (Fig 3B, C, Supplementary Fig 3A-C), consistent with our model that mesothelial
cells acted as an extrinsic source of Msln to impact macrophage differentiation. Additionally,
analysis of ‘reversed’ chimeric mice excluded intrinsic effects of Msln on LPMs as BM transfer
from Msln-/- CD45.2 mice into WT CD45.1 recipients had Gata6 expression in LPMs and lung
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pleural macrophages that was similar to that of BM derived LPMs from littermate WT CD45.2
mice (Fig 3D, Supplementary Fig 3D, E).

We used a second approach to test the role of Msln on LPM Gata6 expression that did not
involve irradiation needed to produce BM chimeras. Adapting a technique used to show the
acquisition of the TRM features of alveolar macrophages by macrophage precursors129, we
adoptively transferred either WT monocytes or bone marrow derived macrophages (BMDMs)
intraperitoneally into untreated Msln-/- or WT littermates. We then harvested peritoneal exudates
12 days post injection. The percentage of the total pool of LPMs represented by the transferred
CD45.1 cells ranged from 0.5 to 1%. Further analysis of the CD45.1 transferred cells showed that
they had acquired features of LPMs (ICAM2+) in both Msln-/- and WT recipient mice. However,
the CD45.1 LPMs in the Msln-/- recipient mice expressed less Gata6 than in WT recipients (Fig
3E-H, Supplementary Fig 3F, G). The percentage and absolute numbers of LPMs were
comparable between WT and Msln-/- mice. Taken together, Msln acts extrinsically to modulate the
expression of Gata6 in TRMs found in mesothelial cell lined cavities.

Muc16 deficiency recapitulates the effects of Msln deficiency on tissue resident macrophages
We identified both Msln and Muc16 as secreted candidates in regulating Gata6 expression in
LPMs. Given its potential interaction with Msln98,152, expression in mesothelial cells (Fig 1E) and
high molecular weight (>2 million Da), we tested if Muc16 was also necessary for Gata6
expression in LPMs. Similar to the Msln-/- mice, the LPMs and pleural macrophages from Muc16/-

mice had lower Gata6 expression as compared to littermate controls (Fig 4A, B, Supplementary

Fig 3H, I). Zymosan-induced peritonitis in Muc16-/- mice showed an increase in recruited
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neutrophils that was similar in magnitude to Msln-/- mice (Fig 4C). Additionally, seven days post
zymosan challenge, Muc16-/- mice contained fewer Gata6+ LPMs, similar to Msln-/- mice tested in
this way (Fig. 4D, Supplementary Fig 3J).

We next tested whether the effect of Muc16 deficiency was extrinsic. Repopulation of
Muc16-/- mice with WT bone marrow cells led to a decrease in Gata6 expression in LPMs and
pleural macrophages as compared to WT recipient mice, an effect similar to repopulation of the
BM in Msln-/- mice (Fig 4E, Supplementary Fig 3K-M). Next, analysis of ‘reversed’ chimeras
further excluded intrinsic effects of Muc16 on LPMs as BM transfer from Muc16-/- CD45.2 mice
into WT CD45.1 recipients had comparable effects on Gata6 expression in LPMs as BM from
littermate WT CD45.2 mice (Fig 4F). After adoptively transferring CD45.1 monocytes and
BMDMs, donor-derived LPMs also expressed lower F4/80 and Gata6 in the Muc16-/- recipient
mice compared to WT (Fig. 4G, H, Supplementary Fig 3N, O). These results support a role for
Muc16 in addition to Msln to promote Gata6 expression in LPMs.
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Figure 2.1 Soluble proteins in peritoneal lavage fluid sustains Gata6 expression in LPMs
(A) Representative FACS plots of isolated LPMs (CD11b+F4/80+ICAM2+). (B) Representative
histograms of Gata6 expression from isolated LPMs (no culture) or LPMs cultured for 24 hours
in media alone (no addition), or media lavaged in the peritoneal cavity (un-fractioned and with
heat denaturation). (C) Average mean fluorescence intensity (MFI) ± SEM of Gata6 for the four
groups of LPMs displayed in B. (D) Average relative expression ± SEM of Gata6 (by qRTPCR) for the four groups of LPMs in B except that LPMs were cultured for 6 hours. (E) The
diagram depicting the number of genes that were expressed at significantly greater levels in
isolated mesothelial cells compared to two other peritoneal cell types, adipocytes and LPMs.
The number of genes making secretory proteins were generated by the gene ontology resource
and literature review. (F) Representative histogram of Gata6 expression from WT LPMs treated
with peritoneal lavage for 24 hours plus either Msln blocking or isotype control antibodies. (G)
Average MFI ± SEM of Gata6 for the experimental design in F. Two different blocking
antibodies directed against Msln (25ug/ml, Antibody 1 and Antibody 2) and their isotype
controls were used. (H) Average expression of soluble Msln ± SEM (by ELISA) from the
peritoneal lavage of WT and Msln-/- mice. The WT lavage was fractionated into >100kD and
<100kD. Dash line labels the limit of detection. (I) Average MFI ± SEM of Gata6 from WT
LPMs treated with unfractionated lavage and fractions >100kDa and <100kDa for 24 hours. (J)
Average expression ± SEM of Gata6 mRNA (by qRT-PCR) in peritoneal lavages:
unfractionated and fractions >100kD and <100kD. Statistical significance in C, D, G-J
determined by a one-way ANOVA followed by Tukey's multiple comparisons post hoc tests.
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (N = 3 independent experiments) In E
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determined by cut-off values 10-4 for adjusted p-value and 4 for log2 fold change to get mesothelial
cell specific genes.
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Figure 2.2. Msln-/- mice have lower expression of specific markers of LPMs
(A) Representative FACS plots of Gata6 and F4/80 expression in isolated LPMs
(CD11b+CD115+MHCIIloICAM2+) from adult Msln-/- and littermate mice. (B) Representative
histograms of Gata6 expression in LPMs from adult Msln-/- and littermate mice. (C) Average
percentage ± SEM of Gata6+ LPMs, (D) average relative MFI expression ± SEM of Gata6 for
LPMs, and (E) average percentage ± SEM of F4/80+ LPMs from adult Msln-/- and littermate
mice.

(F)

Average
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±

SEM
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Gata6+

lung

pleural
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(CD11b+CD115+MHCIIloICAM2+), (G) average relative MFI expression ± SEM of Gata6 for
lung pleural macrophages, and (H) average percentage ± SEM of F4/80+ lung pleural
macrophages from adult Msln-/- and littermate mice. (5 pooled experiments, N = 19 to 20
mice/group). (I) Average number of neutrophils in the peritoneal cavity from zymosan (2×106
particles) -stimulated Msln-/- and littermate 3 hours post injection (3 to 4 pooled experiments, N
= 9 to 12). (J) Average percentage ± SEM of Gata6+ LPMs, (K) average relative MFI
expression ± SEM of Gata6 for LPMs, and (L) average percentage ± SEM of F4/80+ LPMs
from adult Msln-/- and littermate mice 7 days post zymosan (2×106 particles) intraperitoneal
injection. (3 pooled experiments, N = 11 to 14). Statistical significance in C-L determined by a
two-tailed unpaired U-test. **P < 0.01, ***P < 0.001, ****P < 0.0001.

41

42

Figure 2. 3. Msln acts extrinsically on Gata6 expression in the process of TRM
differentiation
(A) Average number of cMoPs (cKitlo Flt3- CD115+ Ly6chi CD11b+ CD11c- Ly6G-) from Msln-/and littermate. Data are representative of two independent experiments. (B) Representative
histograms of Gata6 expression in CD45.1 LPMs in congenically distinct recipients (CD45.2
Msln-/- and littermate) 8 weeks after irradiation and reconstitution. (C) Average relative MFI
expression ± SEM of Gata6 for CD45.1 LPMs from Msln-/- and littermate recipients. (3 pooled
experiments, N = 10). (D) Average relative MFI expression ± SEM of Gata6 for CD45.2 LPMs
in congenically distinct recipients (CD45.1 WT) 8 weeks after irradiation and reconstitution
with Msln-/- and littermate BM. (2 pooled experiments, N = 10). (E) Representative FACS plots
of CD45.1 LPMs (CD11b+CD115+MHCIIloICAM2+) from adult CD45.2 Msln-/- and littermate
mice 12 days post monocyte (2X105 cells per mouse) intraperitoneal injection. (F)
Representative histograms of Gata6 expression in CD45.1 and CD45.2 LPMs displayed in E.
(G) Average relative MFI expression ± SEM of Gata6 for CD45.1 LPMs in congenically
distinct recipients (CD45.2 Msln-/- and littermate) (2 pooled experiments, N = 10). (H) Average
relative MFI expression ± SEM of Gata6 for CD45.1 LPMs in congenically distinct recipients
(CD45.2 Msln-/- and littermate) 12 days post BMDM (2X105 cells per mouse) intraperitoneal
injection. (3 pooled experiments, N = 12 to 14). Statistical significance in C, D, G, H determined
by a two-tailed unpaired U-test. **P < 0.01, ****P < 0.0001.
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Figure 2. 4. Muc16 deficiency recapitulates the effects of Msln deficiency on resident
macrophages
(A) Average relative MFI expression ± SEM of Gata6 for LPMs and (B) average relative MFI
expression ± SEM of Gata6 for lung pleural macrophages from adult Muc16-/- and littermate
mice. (3 to 5 pooled experiments, N = 25 to 31). (C) Average number of neutrophils in the
peritoneal cavity from zymosan (2×106 particles)-stimulated Muc16-/- and littermate 3 hours
post injection (3 pooled experiments, N = 9). (D) Average relative MFI expression ± SEM of
Gata6 for LPMs from adult Muc16-/- and littermate mice 7 days post zymosan (2×106
particles) intraperitoneal injection. (E) Average relative MFI expression ± SEM of Gata6 for
CD45.1 LPMs from Muc16-/- and littermate recipients 8 weeks after irradiation and
reconstitution. (3 pooled experiments, N = 10). (F) Average relative MFI expression ± SEM
of Gata6 for CD45.2 LPMs in congenically distinct recipients (CD45.1 WT) 8 weeks after
irradiation and reconstitution with Muc16-/- and littermate BM. (2 pooled experiments, N =
10). (G) Average relative MFI expression ± SEM of Gata6 for CD45.1 LPMs in congenically
distinct recipients (CD45.2 Msln-/- and littermate) 12 days post monocytes (2X105 cells per
mouse) intraperitoneal injection. (2 pooled experiments, N = 7 to 9) (H) Average relative MFI
expression ± SEM of Gata6 for CD45.1 LPMs in congenically distinct recipients (CD45.2
Msln-/- and littermate) 12 days post BMDM (2X105 cells per mouse) intraperitoneal injection.
(3 pooled experiments, N = 7 to 11). Statistical significance in A-H determined by a twotailed unpaired U-test. **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Supplementary Figure 1. Msln and Muc16 expression in peritoneal mesothelial cells and
LPMs
(A) 29 genes making secretory proteins among 315 mesothelial cell specific genes. (B) Average
relative expression ± SEM of Msln (by qRT-PCR) in LPMs and isolated peritoneal mesothelial
cells. (C) Representative RNA scope images for Msln in fresh-frozen intestine section. Black
arrowheads indicate Msln-positive mesothelial cells. (D) Average relative expression ± SEM of
Muc16 (by qRT-PCR) in LPMs and isolated peritoneal mesothelial cells. (E) Representative
RNA scope images for Muc16 in fresh-frozen intestine section. Black arrowheads indicate
Muc16-positive mesothelial cells. Statistical significance in B, D determined by a two-tailed
unpaired U-test. ND: non-detectable.
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Supplementary Figure 2. The impact of Msln is restrict to tissue resident macrophages
(A) Average number of LPM from Msln-/- and littermate (5 to 7 pooled experiments, N = 20 to
25). (B) Average relative MFI expression ± SEM of Gata6 for LPMs and (C) average percentage
± SEM of F4/80+ LPMs from 2-week-old Msln-/- and littermate mice. (3 pooled experiments, N
= 15). (D) Average percentage ± SEM of Ki67+ LPMs and (E) AnnexinV+PI+ LPMs from
adult Msln-/- and littermate (5 to 7 pooled experiments, N = 23). (F, G) Average percentage ±
SEM of immune cell populations in spleen, Peyer’s patches from small intestine from adult
Msln-/- and littermate. (2 pooled experiments, N = 4 to 10) (H-J) Average number ± SEM of
total peritoneal exudate cells, peritoneal eosinophils, and peritoneal B cells from adult Msln-/and littermate. (3 to 5 pooled experiments, N = 10 to 26). (K) Average relative MFI expression
± SEM of Gata6 for LPMs from adult Msln-/- and littermate mice in the other facility. (3 to 5
pooled experiments, N = 11 to 14) in different facility. (L) Average relative expression ± SEM
of Gata6, Bhlhe40, Cebpb, Nfe2, and Rarb (by qRT-PCR) for LPMs from adult Msln-/- and
littermate mice. (2 5 pooled experiments, N = 4) Statistical significance in A-L determined by
a two-tailed unpaired U-test. *P < 0.05, **P < 0.01, ****P < 0.0001.
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Supplementary Figure 3. Mice with Muc16 deficieny phenocopies mice lacking of Msln
(A) Average percentage ± SEM of Gata6+ CD45.1 LPMs from Msln-/- and littermate recipients
8 weeks after irradiation and reconstitution. (3 pooled experiments, N = 10). (B) Average
percentage ± SEM of Gata6+ CD45.1 lung pleural macrophages and (C) average percentage ±
SEM of Gata6+ CD45.1 lung pleural macrophages from A. (3 pooled experiments, N = 10). (D)
Average percentage ± SEM of Gata6+ CD45.2 lung pleural macrophages and (E) average
percentage ± SEM of Gata6+ CD45.2 lung pleural macrophages in congenically distinct
recipients (CD45.1 WT) 8 weeks after irradiation and reconstitution with Msln-/- and littermate
BM. (3 pooled experiments, N = 10) (F) Average percentage ± SEM of Gata6+ CD45.1 LPMs
in congenically distinct recipients (CD45.2 Msln-/- and littermate) 12 days post monocyte
(2X105 cells per mouse) intraperitoneal injection. (G) Average percentage ± SEM of Gata6+
CD45.1 LPMs in congenically distinct recipients (CD45.2 Msln-/- and littermate) 12 days post
BMDM (2X105 cells per mouse) intraperitoneal injection. (3 pooled experiments, N = 12 to 14).
(H, I) Average percentage ± SEM of Gata6+ LPMs and average percentage ± SEM of Gata6+
pleural macrophages from adult Muc16-/- and littermate mice. (3-5 pooled experiments, N = 25
to 31). (J) Average percentage ± SEM of Gata6+ LPMs from adult Muc16-/- and littermate mice
7 days post zymosan (2×106 particles) intraperitoneal injection. (3 pooled experiments, N = 11
to 12). (K) Average percentage ± SEM of Gata6+ CD45.1 LPMs from Msln-/- and littermate
recipients 8 weeks after irradiation and reconstitution. (3 pooled experiments, N = 10). (L)
Average percentage ± SEM of Gata6+ CD45.1 lung pleural macrophages and (M) average
percentage ± SEM of Gata6+ CD45.1 lung pleural macrophages from K. (3 pooled experiments,
N = 10) (N) Average percentage ± SEM of Gata6+ CD45.1 LPMs in congenically distinct
recipients (CD45.2 Muc16-/- and littermate) 12 days post monocyte (2X105 cells per mouse)
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intraperitoneal injection.

(O) Average percentage ± SEM of Gata6+ CD45.1 LPMs in

congenically distinct recipients (CD45.2 Muc16-/- and littermate) 12 days post BMDM (2X105
cells per mouse) intraperitoneal injection. (3 pooled experiments, N = 7 to 11). Statistical
significance in A-O determined by a two-tailed unpaired U-test. **P < 0.01, ***P < 0.001,
****P < 0.0001.
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Chapter 2: Discussion

Local environment determines the identity of tissue resident macrophages. Here we show that, in
the pleural and peritoneal cavities, Msln and Muc16 derived from mesothelial cells modulates the
expression of Gata6 in macrophage precursors in an extrinsic manner and has functional
consequences in acute peritonitis.

Our results highlight the potential for a potential interaction between Msln and Muc16. In cancer
biology, Msln expression is elevated in several tumor types and is associated with increased tumor
invasion and poor clinical outcome151. However, its role outside of cancer biology is less welldefined, in part because mice lacking Msln were not found to display a phenotype in homeostasis
88

. As a membrane-anchored glycosylphosphatidyl inositol–linked 71-kDa membrane protein

(Msln precursor), Msln is proteolitically cleaved to generate mature Msln (40 kDa) and MPF (30
kDa) that is secreted from the cells147-150.

Msln is known to bind the cell-surface protein Mucin 16 (Muc16) in an N-glycosylation dependent
manner. Muc16 is a membrane spanning mucin that is expressed on ovarian, endometrial, tracheal,
and ocular surface epithelial cells158-160. This mucin is initially expressed on the surface and then
shed in the extracellular milieu following proteolytic cleavage153. Individually, Msln and Muc16
are biomarkers for peritoneal and tumor metastases98,152,161. Despite their influence on
tumorigenesis, we have a poor understanding of the role of Msln and Muc16 in shaping the
microenvironment in the peritoneum and other mesothelium-containing tissues for myeloid cell
differentiation. Given that Muc16-Msln is thought to be ligand-receptor combination, we
examined the effect of Muc16 deficiency on mesothelial-associated TRM identity and found that
mice with loss of Muc16 phenocopied Msln-/- mice.
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The nature of the Msln/Muc16 interaction is still unclear. Previous studies have indicated their
shedding from mesothelium84, while our data suggests that these may form a high molecular
complex. Additionally, the receptor and signaling mechanism in LPMs that leads to the effect of
Msln and Muc16 on Gata6 expression remains to be identified. Other than the interaction between
Msln and Muc16, CD206 (Mannose receptor, Mrc1) has been reported to engage with Msln and
Muc16162,163. One of the features of Gata6f/f, LysM-Cre mice is CD206 positivity of LPMs134, and
in this study we found more CD206+ LPMs in Msln-/- and Muc16-/- animals (data not shown).
Whether there is a direct interaction between CD206 and Msln/Muc16 remains to be studied.
Another candidate Msln/Muc16 receptor is sialic acid binding Ig-like lectin E (Siglec-E). Siglec9, the human Siglex-E homologue, has be identified as the immune cell receptor for MUC16 in
human NK cells and monocytes164-166. Siglec-E changes phosphorylation of Syk and p38 mitogenactivated protein kinase in neutrophils and phosphorylation of Syk in macrophage-mediated
inflammatory responses and diseases167. The exact receptor will need to be determined in future
studies.

Monocytes extravasate through mesothelium into peritoneum in a CCR2-dependent manner168 and
become macrophages42,169. In homeostasis, most LPMs are derived from embryonic precursors
seeded during fetal development42,154,170. Though few in number, Ly6C+ monocytes constitutively
enter the peritoneal cavity in a CCR2-dependent manner and act as precursors of LPMs171. We
have demonstrated that Msln/Muc16 interact with LPMs along their differentiation axis to promote
TRM identity. However, the timing of this interaction along the developmental trajectory of
macrophages and the organism remains unknown. Additionally, whether the cells interacting with
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Msln/Muc16 are in the fluid phase or are adherent to the mesothelium is also unclear. We examined
the capability of peritoneal fluid to induce Gata6 in monocytes and did not detect significant
upregulation (data not shown). At the steady state in adult mice, while a majority are embryonically
derived, a small proportion come from the periphery as monocytes154. In young mice, however,
almost all LPMs are embryo-derived44,172 and do not experience a monocyte stage. We hypothesize
that this potentially explains why we do not detect a difference in Gata6 expression in young mice
and why the effect becomes more significant when original LPMs are replenished by peripheral
monocytes in the settings of aging, irradiation, and inflammation-induced cell death. While we
have identified the importance of Msln and Muc16, the role of other factors from the local
peritoneal environment in defining the identity of TRM remains to be studied.

Msln was first studied as a pro-tumorigenic protein and used as a tumor biomarker. However, the
roles of Msln in other cell types were not well studied108. During homeostasis, expression of Msln
is limited to cavities derived from the intraembryonic coelom which may explain the localized
effect of knocking out Msln and Muc16 at steady state. In contrast to its effect on macrophages,
the loss of Msln seems to have limited effects on mesothelium at the level of proliferation, cytokine
secretion, and adhesion (data not shown). Prior to our study, peritoneal mesothelium was known
to produce M-CSF and other growth factors to support TRM differentiation144. Beyond the role as
an adhesion protein173,174, Msln affected macrophage adhesion, migration, and other macrophage
biology and did not find any difference (data not shown). It was previously reported that Gata6
controls the survival of LPM134,135. However, we did not observe any defect in proliferation and
survival in LPMs from mice lacking Msln/Muc16, even though they shared several features with
Gata6f/f, LysM-Cre mice. We observed fewer Gata6+ LPMs in mice lacking Msln/Muc16, but the
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lower magnitude of the effect may explain why Msln-/- and Muc16-/- mice do not recapitulate every
phenotype in Gata6f/f, LysM-Cre mice, including cell number and certain surface markers40,134,135.
Given that the difference in Gata6+ LPM was greater in mice challenged with different model
injuries, we hypothesis that Msln and Muc16 may play an even more important role outside of
homeostasis that is yet unrecognized.

In the zymosan-induced peritonitis model, we found more neutrophils infiltrated into the peritoneal
cavity in the acute phase46 and less mature macrophages were present in the resolution phase in
both Msln-/- and Muc16-/- animals. However, it is still not clear whether this is due to mesothelial
or myeloid cells, as Msln blockade in surgery-induced peritoneal adhesions109 eliminated adhesion.
Regardless, the interaction between mesothelial cells and LPMs175 and the role of peritoneal
macrophages in peritoneal dialysis patients176 suggests that Msln could be a potential therapeutic
target. Future studies of Msln should clarify its biochemical interactions with Muc16 and potential
receptors, illuminate its role in modulating Gata6 and tissue-specific transcription factors, and
determine its importance outside of homeostasis.
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CHAPTER THREE

Msln orchestrates mucosal repair and tumorigenesis in a macrophage-dependent manner
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Chapter 3: Abstract
Msln is expressed in many different carcinomas, however little is known about the function and
influence of Msln in immune cells residing in the tumors. We found that Msln was one of the most
upregulated genes in epithelial cells after colonic biopsy injury. To determine whether Msln had a
function in this model, we injured WT and Msln-deficient mice. We found that Msln-deficient
mice had more proinflammatory cells in the wound bed. We next hypothesized that Msln had a
similar role in modulating immune cells in APCMin/+ mice to allow for larger polyp growth. We
found that Msln-deficient APCMin/+ mice had on average smaller polyps and the maximum
diameter of polyp in each mouse was smaller than in WT APCMin/+ mice. These results suggest that
epithelial-derived Msln may be functioning to promote a pro-regenerative, pro-tumor
microenvironment by immunosuppression.

58

Chapter 3: Introduction
Msln is expressed in many cancers including intestinal cancers in humans177, though its role in
promoting intestinal cancer is unknown. One model of intestinal cancer is the APCmin/+ mouse
model of intestinal polyposis178. In this mouse model, one allele of adenomatous polyposis coli
(APC) is mutated and polyps start to form throughout the small and large intestine over time by
loss of heterozygosity. The majority of the polyps form throughout the small intestine and several
polyps typically form in the colon. Loss of APC leads to stabilization of β-catenin and activation
of the Wnt signaling pathway.
We were interested in the role of Msln because we found that it was one of the most
upregulated genes in WAE cells compared to uninjured epithelial cells after biopsy injury. Due to
its purported role in adhesion, proliferation, and cancer, we hypothesized that Msln would be
important for proper healing after intestinal epithelial injury. We made Msln conditioned knockout
mice and injured these mice to look for intestinal healing defects. Surprisingly, the major defects
we found were in the mesenchyme within the wound bed once the epithelium-derived Msln was
depleted. There were more Ly6G+ neutrophils within the wound beds compared to WT mice.
These results suggested that Msln was important for controlling inflammation after intestinal
mucosal injury. We also crossed Msln-/- mice with APCmin/+ mice to examine the role of Msln in
intestinal cancer formation and growth. We found that Msln-/- mice had smaller polyps in the small
intestine compared to Msln+/+ mice in this model. These results suggest that Msln may be
important for recruiting and/or maintaining the tumor microenvironment in mesothelin-expressing
carcinomas.
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Chapter 3: Methods and Materials
Mice
Animal experiments were performed in accordance with approved protocols from the Washington
University School of Medicine Animal Studies Committee. APCmin/+ mice were obtained from
Jackson labs and were bred to generate APCmin/+ mice that were WT, heterozygous, or knockout
for Msln.

Polyinosinic-polycytidylic acid [poly(I:C)] injury
Blunted villi were induced by intraperitoneal injection of Poly(I:C) (Sigma) 0.5mg/25g mouse.

Colonic biopsy
We used a high-resolution miniaturized colonoscope system to visualize the lumen of the colon
and discretely injure the mucosal layer in 10-16 week old anesthetized mice. After inflating the
colon with PBS, we inserted 3 French flexible biopsy forceps into the sheath adjacent to the camera.
We removed 3-5 full-thickness areas of the entire mucosa and submucosa that were distributed
along the dorsal side of the colon. All mice were injured with the same technique. For this study,
we evaluated wounds that averaged ~1 mm2, which is equivalent to removal of ~300 crypts.

Colonic tissue preparation
For fixed-frozen sections, wounded mice were sacrificed and perfused transcardially with 4%
paraformaldehyde (PFA).

After dissection, the colon was inflated with 4% PFA, opened

longitudinally, and pinned flat in 4% PFA overnight. The following day the fixed colons were
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incubated in 20% sucrose-PBS for 6 hours. For frozen sections, colons were removed, washed in
PBS, and placed in OCT compound (Tissue-Tek).

For both procedures, each wound bed, including 1-2 mm of adjacent uninjured area, was removed
with a razor blade and frozen in OCT compound. For each individual wound, the material was
oriented so that serial 5-µm-thick sections were obtained in a proximal to distal manner with
respect to the orientation of the in vivo colon. Each wound bed was completely sectioned. To
standardize our analysis, we evaluated the 5-10 sections in the central (largest) portion of a given
wound bed as determined by light microscopic views of unstained sections. Serially numbered,
unstained sections were stored at -80°C until use. One of these sections was stained with
hematoxylin/eosin to confirm orientation.

In situ hybridization
Tissues were fixed in 4% (v/v) paraformaldehyde at 4⁰C for 18 to 24 hours, dehydrated with 20%
sucrose in PBS, and embedded in OCT. Tissue sections cut at a thickness of 5 µm were processed
for RNA in situ detection using the RNAscope 2.5 HD Assay–RED according to the
manufacturer’s instructions (Advanced Cell Diagnostics). RNAscope probes used were MmMSLN (Cat No. 443241).

Immunofluorescence
Fresh-frozen sections of wounds were used for immunofluorescence. Sections were fixed in 4%
PFA, rinsed in PBS, blocked in 3% BSA/0.1% Triton-X for 20 minutes and incubated with primary
antibody for one hour. Slides were then rinsed with PBS, incubated with secondary antibody
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followed by bis-benzimide staining and mounting with Mowiol 4-88 (Calbiochem). Sections were
viewed with a Zeiss Axiovert 200 with Axiocam MRM camera. Antibodies used were rat
monoclonal anti-CD31 (MEC 13.3; BD Biosciences), rat monoclonal anti-KI67 (TEC-3; DAKO),
monoclonal rat anti-F4/80 (CI:A3-1;Caltag Laboratories), and rabbit polyclonal anti-β-catenin
(Sigma). All primary antibodies were used at 1:100 dilution. Appropriate donkey anti-rat or antirabbit secondary antibodies conjugated to Alexa Fluor 488 or Alexa Fluor 594 (Invitrogen) were
used at 1:500 dilution to visualize staining.

Quantification of polyps from APCmin/+ mice.
Mice were sacrificed at four months of age, the small intestine was removed and flushed with PBS,
and the small intestine was inflated with 4% PFA for 30 seconds. The small intestine was then
opened longitudinally and pinned open in 4% PFA and fixed overnight at 4°C. The intestine was
then examined under a stereoscope and each polyp was photographed (Olympus, Tokyo, Japan).
The size and number of each polyp was recorded for each mouse.
Chapter 3: Results
We started our investigation on Msln first because it was one of the most highly upregulated genes
in wound-associated epithelial cells compared to uninjured epithelial cells upon biopsy injury. To
confirm that Msln was expressed specifically in epithelial cells, we performed in situ hybridization
on WT wounds four days after injury (Figure 3.1.A). We found that Msln was only expressed in
WAE cells and was not expressed in any mesenchymal cells. We have also utilized a wellcharacterized poly(I:C)-mediated injury model, known to selectively ablate the small intestinal
villus epithelium with sparing of crypts and showed that Msln was expressed in the WAE cells
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(Figure 3.1.B). As a positive control, Msln expression could be observed in mesothelial cells
lining the outer layer of the intestine.
To study the role of Msln in wound-associated epithelial cells, we obtained and injured
VilCre X Mslnf/f and Mslnf/f mice. We found that injured VilCre X Mslnf/f mice had more Ly6G+
neutrophils 4 days after biopsy injury (Figure 3.2). However, the wound healed comparably
between VilCre X Mslnf/f and Mslnf/f mice by day 12. Taken together, these results suggest that
Msln has an anti-inflammatory role on promoting wound repair.
We next wanted to determine the role of Msln in promoting intestinal polyp formation in
the APCMin/+ model. We crossed APCMin/+ mice with Msln+/- mice to generate APCMin/+ mice that
were wildtype (WT), heterozygous (Het), or knockout (KO) for the Msln gene. We sacrificed mice
at four months of age and counted and measured the size of all polyps in the small intestine. We
found that Msln-/- mice had fewer large polyps (>2 mm diameter) and the largest polyp (maximum
diameter) was smaller compared to WT mice (Figure 3.3). These results suggest that Msln is
required for maximal polyp growth in the APCmin/+ model of intestinal polyposis.
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Figure 3.1. Msln expression in the wound
(A) Representative RNA scope images for Msln in fresh-frozen intestine section. Black
arrowheads indicate Msln-positive wound-associated epithelial cells Poly(I:C) 24 hr post ip.
(B) Representative RNA scope images for Msln in fresh-frozen intestine section. Black
arrowheads indicate Msln-positive wound-associated epithelial cells 4 day post biopsy.
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Figure 3.2. More Ly6G+ neutrophils accumulate in the wound bed in Msln-deficient mice
Sections of colons from (A) VilCre X Mslnf/f and (B) Mslnf/f mice 3 days post-biopsy. The
sections were stained with anti-Ly6G (grey) to detect neutrophils, anti-α-SMA antisera (red) to
detect muscularis propria, anti-β-catenin (green) to detect the epithelium, and bis-benzamide to
label nuclei (blue).
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Fig 3 Msln expression in the WAE-like cell and the impact on the number of polyps
(A) Representative RNA scope images for Msln in fresh-frozen intestine section. Black
arrowheads indicate Msln-positive WAE-like cells (B) Graph of the average number of small
intestinal polyps less than 1 mm, 1-2 mm, and greater than 2 mm in ApcMin/+ mice sacrificed at 4
months of age. n=13 WT, n=20 Het, n=17 KO mice. ANOVAs were run between WT, Het, and
KO for each category of size of polyps and only polyps greater than 2 mm had a significant
difference. ****P<0.0001 by Tukey's post-test.
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Chapter 3: Discussion
We showed the impact of Msln on tissue resident macrophage differentiation in the
peritoneum. In other microenvironments, e.g. epithelium, Msln may also modulate the
differentiation of infiltrated monocytes. Msln is known to be expressed by intestinal epithelium in
a YAP dependent manner during Apc mutant aberrant crypt foci179 and by wound associated
epithelial-like cells in our in vitro primary epithelial cell culture system180. We hypothesized that
understanding the role of Msln in colonic wound repair would also shed light on the role of Msln
during cancer. Our data would suggest that this may interact with tissue-resident or infiltrating
myeloid cells and modulate their function. Tumors have been described as wounds that do not heal
because many of the processes required for wound repair are also required for tumor growth181. In
APCMin/+ mice, there was no significant difference in the number of small or medium sized polyps,
suggesting that Msln is not required for the initiation of polyps but instead is important for their
growth above 2 mm. Although speculative, our work would indicate that Msln may function in
cancer to adjust the tumor microenvironment to produce a M2-skewed macrophage phenotype
which is beneficial to the tumorigenesis.

Msln was originally discovered as a cytokine that could act similarly to IL-6 in a
megakaryocyte colony-forming assay149, though the majority of the recent research on this gene
has been investigating its role as a membrane protein expressed on cancer cells182. It is also
utilized as a target for antibody-based cancer immunotherapies. Our results suggest that Msln
may be acting as a cytokine in our wound healing and tumorigenesis model because the major
defects were seen in cell types that do not express Msln. Future studies should determine which
portions of Msln were required for granulation tissue formation (MPF, mature Msln, or both);
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which cell type(s) are influenced by the different microenvironments. Additionally, direct
blockade of Msln using neutralizing antibodies may be an attractive therapeutic approach for
Msln-expressing cancers, since Msln is not thought to have any role under homeostatic
conditions88.
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CHAPTER FOUR
Summary and Future Directions
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Summary
As a heterogeneous population of immune cells, TRMs fulfill tissue-specific and niche-specific
functions. These cover from well-regulated homeostatic functions to central roles in tissue immune
surveillance, response to infection and the resolution of inflammation. Recent studies highlight
marked differences in the origins of tissue macrophages that arise from hematopoietic versus selfrenewing embryo-derived populations. Understanding the mechanisms that dictate TRM
heterogeneity should explain why conventional models of macrophage activation, i.e. BMDM, do
not interconvert the extent of heterogeneity seen in vivo.

In addition to delineating transcriptional modulation within tissue resident macrophages, we
provide new insights about the role of niche factors in shaping the identity of these unique cells.
Dietary derived retinoic acid induces LPM-specific TF Gata6 expression. We hypothesized that
microenvironment also imprints the TRMs because of proximity. We accessed the effect of soluble
proteins from mesothelium-lining serous cavities on Gata6 regulation. We next did informatics
analysis to identify potent candidates. We also applied both BM chimera and adoptive transfer
approaches to validate if the mechanism of Msln/Muc16-mediated Gata6 regulation acts
extrinsically. We found that mesothelial derived Msln and Muc16 induce Gata6 expression at both
steady state and inflammation, which further influence the immune responses to sterile
inflammation and pathogen infection. Targeting both ligands may provide a new therapeutic
approach for macrophage-related diseases.

On the other side, there are many macrophage-related intestinal diseases that are characterized by
inflammation and loss of crypts, though the mechanisms by which the mucosa regenerates after
70

injury are unclear. We utilized a colonic biopsy injury system to create focal wounds in the distal
colon of mice to study the mechanisms of mucosal repair. We hypothesized that understanding
mucosal repair would provide insight into the mechanisms of intestinal diseases that involve loss
of crypts and/or incomplete healing such as IBD.

We evaluated epithelial-derived genes stimulated after injury and surprisely found that Msln was
upregulated during inflammation. We found that Msln-deficient mice had more proinflammatory
cells in the wound bed. Also, Msln-deficient APCMin/+ mice had smaller polyps in the small
intestine than APCMin/+ mice. It suggests that Msln is an epithelial-derived factor that is required
to stimulate tissue repair after epithelial injury or carcinoma.

The findings described in this thesis suggest that tissue-specific factors are critical for TRM
differentiation and colon regeneration after mucosal damage. These results may eventually lead to
therapies that establishing macrophages for repair (locally-injected recombinant Msln) or inhibit
pro-tumorigenesis to limit tumor growth (anti-Msln therapy).
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Future directions
Msln and Mucin16 as targets for tissue immunity

We found that mesothelial cell-derived Msln and Muc16 imprint Gata6-positive TRMs and WAE
cell-derived Msln modulates the microenvironment in the wound bed. But the signaling pathways
for both phenomena are still unknown. Given that Gata6 defect results in abnormal immune
responses during inflammation, we presumed that both proteins immune-modulate the TRMs to
resolve the inflammation properly. We are continuing to generate recombinant Msln and MPF to
rescue the defect we found in mice lack of Msln and Muc16.

The other direction is to find the receptor for both Msln and Muc16. The receptor and signaling
mechanism in LPMs that leads to the effect of Msln and Muc16 on Gata6 expression remains to
be identified. By literature research, we found two candidates, Mrc1 and Siglece, which interact
with either Msln or Muc16. We found that both WT and Mrc1-/- CD45.2 BM-derived cells
colonized the peritoneum and pleura of WT CD45.1 recipient mice to produce comparable number
of Gata6+ tissue resident macrophages in the peritoneum and lung pleura. After adoptively
transferring either CD45.2 WT or Mrc1-/- monocytes and BMDMs, donor-derived LPMs has
similar F4/80 and Gata6 expression in the WT recipient mice. To examine the other target, we are
planning to get Siglece reagents.

The other part is to figure out which portions of Msln have the bioactivity in modulating Gata6
expression in tissue resident macrophages. We are currently generating MPF, mature Msln, or fulllength non-cleavable forms of Msln so that we can purify the proteins and test their ability to
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directly stimulate pre-macrophages such as monocytes and BMDMs. These experiments should
provide some clues as to which portions of Msln are responsible for LPM differentiation.

We hypothesize that there is a common mechanism for the accumulated pro-inflammatory cells
seen in colonic wounds and the smaller polyps seen in APCMin/+ mice. Msln expression is
associated with a worse prognosis in cancer patients and Msln is commonly thought to function as
a cell-intrinsic tumor-promoter182. Although Msln expression appears to be important for cellintrinsic effects in cancer, our wounding experiments suggest that Msln may have an effect on a
broader range of cell types than previously appreciated. Our hypothesis is that Msln has antiinflammatory capability and its expression in carcinomas is important for recruitment and/or
establishment of the tumor microenvironment. Macrophages are one of the major cell types that
are recruited to both colonic wounds and tumors. Tumor associated macrophages are required for
tumor growth and may explain why polyps were smaller in Msln-/-;APCMin/+ mice compared to
WT;APCMin/+ mice. Future studies should investigate whether there are reduced macrophages in
Msln-/- polyps, and whether blocking Msln may be an effective approach to treating Msln-positive
tumors.
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